Health Trials

Clinical trials

4

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors

An open-label drug-drug interaction study to evaluate the effects of pralsetinib (Gavreto) on the pharmacokinetics of a CYP450 probe substrate cocktail and, in female participants, a hormonal probe substrate, in participants with rearranged during transfection (RET) fusion- or mutation-positive solid tumors

Participants needed: 12
Trial details
Phase: Phase 4Age: 18+Biological sex: AllType: InterventionalSponsor: Rigel PharmaceuticalsUpdated: Aug 10, 2026Locations: 2
Eligibility criteria

Must be willing and able to participate and comply with all study requirements a... [+17]

Clinically relevant abnormal medical history, abnormal findings on physical exam... [+28]

Read more
Status: Recruiting

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

A open-label drug-drug interaction (DDI) study to evaluate the effects of olutasidenib on the pharmacokinetics (PK) of a CYP450 and OATP1B1 probe substrate cocktail in participants with IDH1 mutation-positive malignancies.

Participants needed: 16
Trial details
Phase: Phase 4Age: 18+Biological sex: AllType: InterventionalSponsor: Rigel PharmaceuticalsUpdated: Aug 11, 2026Locations: 2
Eligibility criteria

Adult male or female ≥ 18 years of age at the time of signing the informed conse... [+10]

Female patients who are pregnant or breastfeeding. [+16]

Read more
Status: Recruiting

Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)

Phase 1b Study of R289 in Patients with Lower-risk Myelodysplastic Syndromes (LR MDS)

Participants needed: 86
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Rigel PharmaceuticalsUpdated: Aug 10, 2026Locations: 15
Eligibility criteria

Patient must be ≥ 18 years of age at the time of signing the informed consent. [+13]

Prior treatment for MDS (i.e., TPOs, EPOs, luspatercept, HMAs) concluded < 4 wee... [+15]

Read more
Status: Recruiting

Study of Olutasidenib and Temozolomide in HGG

The goal of this study is to determine the efficacy of the study drug olutasidenib to treat newly diagnosed pediatric and young adult patients with a high-grade glioma (HGG) harboring an IDH1 mutation. The main question the study aims to answer is whether the combination of olutasidenib and temozolomide (TMZ) can prolong the life of patients diagnosed with an IDH-mutant HGG.

Participants needed: 60
Trial details
Phase: Phase 2Age: 12-39Biological sex: AllType: InterventionalSponsor: Rigel PharmaceuticalsUpdated: Jun 12, 2026Locations: 20
Eligibility criteria

Stratum A: Patients with localized, intracranial, non-pontine, and non-thalamic... [+23]

Pregnancy or Breast-Feeding: Pregnant or breast-feeding women will not be entere... [+26]

Read more